A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Clinical trial NCT02035657 · COMPLETED
Trial details
- NCT number
- NCT02035657
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-01
- Primary completion
- 2018-03-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.